

Freedom of Information Request - FOI2024/259

Thank you for your Freedom of Information request.

Q1. How many patients have been treated (for any condition) in the last 4 months with:

- Benralizumab
- Dupilumab
- Omalizumab
- Reslizumab
- Mepolizumab
- Tezepelumab

Q2. Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age-groups:

- Age 6-11
- Age 12-17
- Age 18 and above

Q3. How many patients have been treated in the last 4 months by the Respiratory Medicine department ONLY with:

- Dupilumab
- Omalizumab

I have considered your request and have set out the Trust's response below:

Q1&2.

	0 – 17	18 +	Total
Benralizumab	0	6	6
Dupilumab	0	64	64
Omalizumab	0	7	7
Reslizumab	0	0	0
Mepolizumab	0	Less than 6*	Less than 6*
Tezepelumab	0	Less than 6*	Less than 6*

Q3.

	Total
Dupilumab	Less than 6*
Omalizumab	Less than 6*

* Please note that the exact number of patients has been withheld and instead a range of below 6 has been provided, as this relates to a low number. Statistically low information can potentially

Glen Burley, Chief Executive

Russell Hardy, Chairman

identify individuals' data, especially due to the rural nature and low population of the county. It would be, in my view, possible to identify them if this data were to be provided to you. The data therefore consists of personal data and as such has been withheld under Section 40(2) of the Freedom of Information Act 2000.

Yours sincerely,

Freedom of Information Officer

Glen Burley, Chief Executive

Russell Hardy, Chairman